

**GOVERNMENT OF NCT of DELHI
DEPARTMENT OF HEALTH & FAMILY WELFARE**

ORDER

F No. PA/SSSHFW/2021/ Amphotericin- B /CD-112648651/5.23/233 Dated :18.5.2021

In order to streamline and systematize the distribution of **Amphotericin- B** injections, to prevent the indiscriminate use of this injection and to establish a transparent, efficient and time-bound system of distribution of this drug to the needy and hospitalized COVID-19 patients on clinically approved evidence-based grounds and ethical principle of distributive justice across Delhi, the competent authority has approved the constitution of a 4 member Technical Expert Committee (TEC) as follows:

- 1) Dr. M. K. Daga (Pulmonologist), as Chairman.
- 2) Dr. Manisha Aggarwal (Anesthesia Branch, MAMC)
- 3) Dr. S. Anuradha (Medicine Branch, MAMC)
- 4) Dr Ravi Mehar (ENT Branch, MAMC)

2. Further, the following steps are prescribed to approve the distribution/supply of Inj. **Amphotericin- B** to notified COVID Hospitals (Govt and Private) only for the treatment of COVID-19 patients:

i. **Application:** All the COVID Hospitals requiring Injection **Amphotericin- B** for treatment of COVID-19 patients shall apply to the Technical Experts Committee.

ii. The application will be the Proforma (**Annexure-B**) to be sent to the TEC through notified e-mail(lipoamphb@gmail.com) or physical copy. No application without filled proforma or incomplete Proforma will be entertained.

iii. The TEC will meet atleast twice every day (preferably 10-11am in the morning and 4-5 PM in the evening) to scrutinize the applications received and facilitate rapid decision making, as time is of the essence in such cases. The meetings can be held on a virtual/digital platform. The guiding principles for TEC shall be evidence based clinically approved parameters as well as principles of equity, distributive justice and transparency.

iv. DGHS shall coordinate with the TEC and facilitate rapid decision making and also monitor the overall management of drug from approval till delivery to the Hospital concerned.

v. The decision of daily meetings will be conveyed to all the stakeholders through e-mail and reasons for refusal will be written and informed to the requisitioning Hospitals. A daily summary of the decisions of the TEC and the allocation made to the hospitals shall also be displayed on the website of DGHS/Health Department.

vi. On recommendation of the TEC, the o/o DGHS shall issue the drug to the authorized representative of the Government Hospital/institution concerned or the CFA/Stockist shall release to the authorized representative of the Private Hospital concerned (in this case, on payment basis) as the case may be.

vii. DGHS and all the CFAs/Stockists will ensure the issuance of drug on same day to the Government and Private Hospital concerned. Respectively, All relevant records shall be maintained by o/o DGHS.

viii. The concerned Govt/Private hospital will submit report regarding usage of drug for the approved patient only.

ix. It shall be the personal responsibility of the Hospital Administration of the institutes requisitioning **Amphotericin- B** to ensure appropriate use of prescription medicine, prevent any misuse/pilferage, coordination with health authorities and to keep proper records so that they are available for audit purpose later.

x. The distribution of **Amphotericin- B** Injections will be made up till the stock remains as per the allocation of Government of India. No waiting list shall be made.

xi. For arrival of fresh stocks, applications will be called afresh after notifying all hospitals for arrival of stocks.

xii. In special circumstances Pr Secretary (H&FW) may allocate injections to any Government Hospitals/ Hospitals run by Government Agencies on special recommendation by the treating doctor.

RK
18/5/2024

Raj Kumar

Spl. Secretary, (H&FW)

To,

1. Director, DGHS, GNCTD
2. TEC Members, GNCTD through **Dr. M. K. Daga**
3. MS/Nodal Officer of all Government Hospitals, GNCTD through DGHS
4. MS/Nodal Officer of all Private Hospitals, GNCTD through **Dr. R. N. Dass**
5. All C&FAs/Stockiest of **Amphotericin- B** through Dy. Drug Contorller

Copy for information :

1. So to CS, GNCTD
2. State Nodal Officer, GNCTD
3. PS to Pr. Secretary, (H&FW), GNCTD
4. Drug Controller, GNCTD

Copy for information to :

1. Secretary to Health Minister, HFW, GNCTD

RK
18/5/2024

Raj Kumar

Spl. Secretary, (H&FW)

**GOVERNMENT OF NCT OF DELHI
DEPARTMENT OF HEALTH & FAMILY WELFARE**

Technical Expert Committee to decide about Amphotericin B (Antifungal drug)

Only a multidisciplinary team or 4 Members team consisting of physician involved in Covid patient care (to be signed by at least two) can recommend the use of Amphotericin B.

The following parameters have to be considered and recorded:

Approx. Body Weight _____

Risk Factors	Yes/No
Diabetes	
On steroids	
On mechanical ventilation	

Condition	Yes/No
New Onset Fever	
H/o suggestive of nasal congestion, purulent discharge, headache, sinus pain	
Swelling of eyes/proptosis	
Nasal ulceration or necrosis	
Decreased vision	
Cranial nerve palsies	
New onset pneumonosis with haemoptysis.	
New onset abdominal pain & hematemesis	

Investigations*	Yes/No
KOH mount hyphae seen (Y/N)	
Histopathology	
Sinus Endoscopy	
CT/MRI	
Culture/MALDI - TOF	
PCR	

*Attach report of any one of the above investigations.

This is certified that Mr/Ms/Mrs.....S/O/D/O/W/O.....

Aged.....yrsAddress.....presently admitted
in Institution/Hospital (name).....

Hospital admission ID No.....DOA.....(DD/MM/YYYY)

is suffering from Covid – 19 and having fungal infection and require Amphotericin B (Dose.....)

Treating Hospital contact person:

Name	Contact No.	Email

Intensivist/Physician/
Respiratory Physician/ENT Specialist

Place:

Date: